The significance of defining preclinical or prodromal Parkinson's disease.
about
Biomarkers of Parkinson's disease: present and futurePharmacological Alternatives for the Treatment of Neurodegenerative Disorders: Wasp and Bee Venoms and Their Components as New Neuroactive ToolsHippocampal α-synuclein and interneurons in Parkinson's disease: Data from human and mouse models.Differential degradation of motor deficits during gradual dopamine depletion with 6-hydroxydopamine in mice.Periodontal health and caries prevalence evaluation in patients affected by Parkinson's diseaseCOPPADIS-2015 (COhort of Patients with PArkinson's DIsease in Spain, 2015), a global--clinical evaluations, serum biomarkers, genetic studies and neuroimaging--prospective, multicenter, non-interventional, long-term study on Parkinson's disease progCan we clinically diagnose dementia with Lewy bodies yet?Idiopathic REM sleep behaviour disorder in the development of Parkinson's diseaseT2-Imaging Changes in the Nigrosome-1 Relate to Clinical Measures of Parkinson's Disease.Neuropathological Staging of Brain Pathology in Sporadic Parkinson's disease: Separating the Wheat from the Chaff.α-Synuclein in the olfactory system in Parkinson's disease: role of neural connections on spreading pathology.Review: Sporadic Parkinson's disease: development and distribution of α-synuclein pathology.α-Synuclein staging in the amygdala of a Parkinson's disease model: cell types involved.Cognitive changes in prodromal Parkinson's disease: A review.Can we define "pre-motor" Parkinson's disease?Measurements of auto-antibodies to α-synuclein in the serum and cerebral spinal fluids of patients with Parkinson's disease.Recent Advances in Biomarkers for Parkinson's Disease
P2860
Q24170134-1D6AFE19-24A2-42F1-9DBD-68C0D2CADC3DQ26795786-80327286-099C-47BC-A4DE-818CF0DB8FA6Q31060511-15FC27AE-CB55-45B5-A581-EC70515759B2Q35922870-CF93A0B5-4A70-43A6-AC04-6BFB09C781FEQ36516071-9AF2825B-F634-4706-B0B0-BF476881A0D1Q36616565-7905AD3A-44CB-471B-9044-C1390161B4E4Q36618103-AED416C1-6C89-4851-BE74-6937C05CA770Q36656691-35E6E424-1D1F-4EB3-9292-7D06ED740CCFQ37351959-9F6C60B1-BAD1-42B4-A127-5796AFA8949CQ37693339-21DEB843-76D3-4383-825D-EEE2463FB0E9Q38153587-10F797AB-26D0-4937-93D7-940D7999DD9AQ38667942-21345F16-C642-4BF0-A76F-69CACB8C461FQ44281222-5D0B0FE5-CE34-4935-B04D-FCD31D8BD92AQ47860019-DC73AB1B-418A-42E5-B644-0366EDBF6CC7Q48565241-3A45C2DE-97F8-499D-ACFE-DDAD65DD9591Q51766023-065EB832-2022-48C6-8715-DD5BD118540DQ58572579-F83AAB08-2A91-49E8-BEB0-526985E19451
P2860
The significance of defining preclinical or prodromal Parkinson's disease.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
The significance of defining preclinical or prodromal Parkinson's disease.
@en
type
label
The significance of defining preclinical or prodromal Parkinson's disease.
@en
prefLabel
The significance of defining preclinical or prodromal Parkinson's disease.
@en
P2860
P356
P1433
P1476
The significance of defining preclinical or prodromal Parkinson's disease.
@en
P2093
José A Obeso
P2860
P304
P356
10.1002/MDS.25019
P407
P577
2012-04-01T00:00:00Z